Idiopathic Pulmonary Fibrosis
Buloxibutid well tolerated, increases lung function in IPF
SAN DIEGO — Among patients with idiopathic pulmonary fibrosis, twice-daily buloxibutid for 36 weeks significantly improved FVC, according to research presented at the American Thoracic Society International Conference.
Lysophosphatidic acid receptor 1 antagonist slows time to disease progression in IPF
SAN DIEGO — Taking an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks slowed time to disease progression in idiopathic pulmonary fibrosis, according to a presentation at the American Thoracic Society International Conference.
Hedgehog pathway inhibitor safe, improves lung function in IPF
SAN DIEGO — After receiving a hedgehog pathway inhibitor for 12 weeks, adults with idiopathic pulmonary fibrosis had better lung function, according to research presented at the American Thoracic Society International Conference.
Patients with IPF experience similar 48-week FVC declines with pamrevlumab, placebo
SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.
Tool predicts new-onset exertional, resting hypoxemia in patients with fibrotic ILD
A tool that includes age, BMI, two lung function measures and a diagnosis of idiopathic pulmonary fibrosis can predict new-onset exertional and resting hypoxemia in fibrotic interstitial lung disease, according to study results.
JNK inhibitor slows lung function decline in idiopathic pulmonary fibrosis
Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.
Zinpentraxin alfa comparable to placebo in idiopathic pulmonary fibrosis
Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.
High oral microbial diversity linked to poor lung function, mortality risk in IPF
Among patients with idiopathic pulmonary fibrosis, higher microbial diversity in the mouth negatively impacted lung function, according to results published in American Journal of Respiratory and Critical Care Medicine.
Low dose morphine lowers objective cough frequency in IPF
Receiving a 5 mg dose of controlled-release morphine twice daily for 14 days lowered objective cough frequency in patients with idiopathic pulmonary fibrosis, according to results published in The Lancet Respiratory Medicine.
ILD treatment differs by sex, race across countries
The prevalence of patients with interstitial lung disease who receive treatment varied across countries, with some sex- and race-based differences, according to results published in CHEST.